Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
US11939582B2 · kind B2 · utility
0Cited by
2References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 20, 2019 |
| Grant date | Mar 26, 2024 |
| Priority date | — |
| Expiry date | Aug 20, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/346
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of sodium voltage-gated channel alpha subunit 2 (SCN2A) in a subject. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a sodium voltage gated channel alpha subunit 1 (SCN1A) related disease or disorder (e.g., Dravet syndrome) in a subject in need.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.